Synonyms: AB-928
Compound class:
Synthetic organic
Comment: AB928 is an oral dual antagonist of the adenosine 2A and 2B receptor isoforms [4]. It was developed to counteract adenosine-mediated immune suppression in the tumour microenvironment by targeting A2AR-expressing T and NK cells and A2A/2BR-expressing myeloid cells.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
AB928 has advanced to Phase 2 clinical evaluation in patients with various solid tumour types. Safety and tolerability results have been published [4]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04381832 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Phase 1/Phase 2 Interventional | Arcus Biosciences, Inc. | ||
NCT04262856 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Phase 2 Interventional | Arcus Biosciences, Inc. | ||
NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Phase 1 Interventional | Arcus Biosciences, Inc. | ||
NCT03720678 | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | Phase 1 Interventional | Arcus Biosciences, Inc. |